Author name: DrugPatentWatch

Generic drug approval is, at its core, a race with rules. The company that reads the rules fastest and most […]

Biosimilar-to-Biosimilar Switching: The Complete IP, Clinical, and Market Playbook For pharma IP teams, portfolio managers, R&D leads, and institutional investors

The 55% figure should stop every pharma IP team in its tracks. That is the share of new small-molecule drugs

Generic drug development has never been a solo endeavor, but the industry has spent the last decade pretending otherwise. Companies

The average generic drug program takes 3 to 4 years from target identification to FDA approval. For most companies, that

Strategic Patent Barriers and Market Exclusivity in the Pharmaceutical Industry Pharmaceutical companies use patent portfolios to prevent generic and biosimilar

How AI, blockchain, multi-sourcing, and smarter policy can cut costs, eliminate fragility, and keep patients supplied Generic drugs fill 89%

A technical deep dive for pharma IP teams, R&D leads, and institutional investors Master Key Takeaways A drug’s market monopoly

For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need more than headline growth figures. Executive Summary